Evidence map›Paper›PMID 41572104›Full record

ArticleDiscover oncology2026

Chemotherapy combined with tislelizumab for a male patient with primary pulmonary choriocarcinoma: a case report and literature review.

Xue Pan, Yongjian Pei, Ting Chen, Yuehua Xu, Minhua Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xue PanDepartment of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Yongjian PeiDepartment of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Ting ChenDepartment of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Yuehua XuDepartment of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. xuyuehua4321@163.com.
Minhua ShiDepartment of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. shiminhua2021@163.com.

Funding

Suzhou Science and Education Strengthening HealthProject QNXM2024019Suzhou Science and Technology Innovation Project for Applied Basic Research SYWD2024113
6 · The paper itself

Abstract

Primary pulmonary choriocarcinoma (PPC) in males is an extremely rare extragonadal malignant trophoblastic tumor with an unclear pathogenesis. Its clinical manifestations are heterogeneous and often mimic more common conditions, leading to frequent misdiagnosis. Moreover, PPC is characterized by early metastatic potential, and currently, no standardized treatment guidelines exist. Here, we report the case of a male patient with PPC who was treated with a combination of chemotherapy and immunotherapy. We also provide a comprehensive review of the literature to enhance understanding of this rare entity, improve early diagnostic accuracy, and explore potential therapeutic strategies.

Indexed as

ChemotherapyImmunotherapyMalePrimary pulmonary choriocarcinoma

Identifiers

PMID41572104
PMCPMC12909730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.